Rationale Carotid endarterectomy (CEA) and medical therapy were shown superior to medical therapy alone for symptomatic (Z50%) and asymptomatic (Z60%) stenosis. Carotid angioplasty stenting (CAS) offers a less invasive alternative. Establishing safety, efficacy, and durability of CAS requires rigorous comparison with CEA in symptomatic and asymptomatic patients. Aims The objective is to compare the efficacy of CAS versus CEA in patients with symptomatic (Z50%) or asymptomatic (Z60%) extracranial carotid stenosis. Design The Carotid Revascularization Endarterectomy vs. Stenting Trial (CREST) is a prospective, randomized, parallel, two-arm, multi-center trial with blinded endpoint adjudication. Primary endpoints are analyzed using standard time-toevent statistical modeling with adjustment for major baseline covariates. Primary analysis is on an intent-to-treat basis. Study Outcomes The primary outcome is the occurrence of any stroke, myocardial infarction, or death during a 30-day peri-procedural period, and ipsilateral stroke during followup of up to four years. Secondary outcomes include restenosis and health-related quality of life.
Introduction
Carotid endarterectomy (CEA) is a standard treatment for prevention of stroke depending upon severity of carotid stenosis and other preoperative factors (1, 2) . Carotid artery stenting (CAS) is an alternative to CEA, but the relative efficacy of these procedures is not well described. Early randomized clinical trials (RCTs) were criticized for inadequate sample size, sub-optimal interventionalist experience, inconsistent use of anti-platelet medications, absence of an anti-embolic device, and incomplete enrollment (3) (4) (5) . The Carotid Revascularization Endarterectomy vs. Stenting Trial (CREST) was designed to minimize the impact of these issues, and is the only RCT to enroll symptomatic and asymptomatic patients.
Method
Design CREST is a prospective, randomized, multi-center trial, with blinded endpoint adjudication, designed to compare the efficacy of CAS versus CEA. All institutions received Institutional Review Board or equivalent ethics committee approval before trial initiation, and all participants provided written informed consent.
Surgical and Interventional Management Committees (SMC & IMC) approved participation of surgeons and interventionalists. For interventionalists, a lead-in phase included a credentialing period, during which each interventionalist performed up to 20 stent procedures using ACCULINKt and ACCUNETt devices (6) . The IMC reviewed the results and approved interventionalists prior to their participating in the randomized phase. For surgeons, the SMC used approaches proven successful in the Asymptomatic Carotid Atherosclerosis Study (ACAS) (7) where approximately the past 50 procedures for each surgeon were reviewed prior to approval for participation in the trial (8) . In the presence of bilateral stenosis treatment of the non-study artery must take place at least 30 days prior to randomization, or 430 days after the study procedure is completed. 5. Expected ability to deliver the stent to the lesion. to place patient at risk of hemorrhagic conversion during the procedure. 9. Hemorrhagic transformation of an ischemic stroke within the past 60 days. 10. Hgb o10 g/dl, platelet count o125 000/ml, uncorrected INR 41Á5, bleeding time 41 min beyond upper limit normal, or heparin-associated thrombocytopenia. 11. Any condition that precludes proper angiographic assessment or makes percutaneous arterial access unsafe. 12. Neurologic illnesses within the past two years characterized by fleeting or fixed neurologic deficit which cannot be distinguished from TIA or stroke. 13. Actively participating in another drug or device trial that has not completed the required protocol follow-up period. 14. Inability to understand and cooperate with study procedures or provide informed consent. 15. Chronic atrial fibrillation. 16 Other cardiac sources of emboli such as left ventricular aneurysm, intracardiac filling defect, cardiomyopathy, aortic or mitral prosthetic heart valve, calcific aortic stenosis, endocarditis, mitral stenosis, atrial septal defect, atrial septal aneurysm, or left atrial myxoma. 17. Any episode of paroxysmal atrial fibrillation within the past 6 months, or history of paroxysmal atrial fibrillation requiring chronic anticoagulation. 18. MI within previous 30 days. 19 . Recent GI bleed that would interfere with antiplatelet therapy. 20. Non-surgical or a high risk surgical candidate defined as the presence of any one of the following: Knowledge of two or more proximal or major diseased coronary arteries with Z70% stenosis that have not, or cannot be revascularized.
Ejection fraction o30% or New York Heart Association (NYHA) Functional Class III or higher.
Unstable angina defined as rest angina with ECG changes. Currently on a list for major organ transplantation (i.e., heart, lung, liver, kidney) or is being evaluated for such.
Malignancy or respiratory insufficiency limiting life expectancy to o5 years or FEV 1 o30% (predicted).
Dialysis dependent renal failure. Uncontrolled diabetes defined as fasting glucose 4400 mg/dl and ketones 412. 
Clinical trial protocols
Asymptomatic Carotid Surgery Trial (9) reported benefit for CEA in individuals with high-grade asymptomatic stenosis. In the United States the majority of revascularization procedures are performed for asymptomatic carotid artery disease (10) . All potential CREST participants were evaluated by the study team's neurologist, interventionalist, vascular surgeon or neurosurgeon, and coordinator, to verify eligibility.
Randomization
Randomization was stratified by clinical center and symptomatic status, and permuted block 1 : 1 randomization was performed within strata using block size randomly chosen from small multiples of two. Randomization occurred when the patient, surgeon, and interventionalist were able to schedule the procedure within two weeks.
Treatment CAS procedures were performed using ACCULINKt and ACCUNETt devices where feasible. CAS patients received aspirin 325 mg b.i.d. and clopidogrel 75 mg b.i.d 48 hours prior to the procedure (Table 3) , or alternatively two aspirin (325 mg) and six clopidogrel (75 mg) given at least four hours pre-procedure. Post-procedure, CAS patients received aspirin 325 mg b.i.d. daily for 30 days and one daily thereafter. During the 30 days post-procedure, CAS patients were to receive either one clopidogrel (75 mg) or one-two ticlopidine (250 mg) daily.
Forty-eight hours before CEA, patients were to receive aspirin (325 mg) daily and remain on aspirin (325 mg) daily indefinitely (at least one year). For those intolerant at this dose, alternatives included ticlopidine (250 mg) b.i.d., clopidogrel (75 mg) daily, aspirin (81 mg) daily, or Aggrenox s b.i.d.
Primary outcome
The primary endpoint is the composite of any stroke, MI, or death during a 30-day peri-procedural period, or ipsilateral stroke through follow-up of up to four years. Separate analyses for the Food and Drug Administration (FDA) device evaluation will assess treatment differences in the one-year composite of stroke, MI, or death during a 30-day peri- surrounded by contrast, seen in multiple angiographic projections, in the absence of angiographic evidence of calcification) that is not associated with an ulcerated target lesion. 5. Abnormal angiographic findings that constitute a contraindication to CEA: ipsilateral intracranial or extracranial arterial stenosis greater in severity than the lesion to be treated, cerebral aneurysm Z5 mm, AVM (arteriovenous malformation) of the cerebral vasculature, or other abnormal angiographic findings that constitute contraindication to CEA. 6. Bilateral carotid stenosis if intervention is planned within the 30day CREST periprocedural period.
Occlusion [Thrombolysis In Myocardial Infarction Trial (TIMI 0)]
'string sign' 41 cm of the ipsilateral common or internal carotid artery. procedural period and stroke ipsilateral to the study artery between 31 days and one year. Suspected endpoint events were reviewed by two Adjudications Committee reviewers masked for treatment group, with disagreements resolved by a third reviewer. Recurrent or new ischemic stroke is defined as an acute neurological event lasting Z24 hours with focal symptoms and signs. The endpoint review process is initiated in the case of a significant neurological event, a positive TIA/Stroke questionnaire, or a two-point or greater increase in the National Institutes of Health Stroke Scale (NIHSS) score. Peri-procedural MI is determined by symptoms, electrocardiography (ECG), and enzyme abnormalities. ECGs are centrally read using the Novacode (11) modification of the Minnesota Code for MI classification. A patient will be considered to have experienced a MI when there is confirmatory evidence of myocardial ischemia plus elevation of cardiac biomarkers (CK-MB or troponin) to a value two or more times the individual clinical center's laboratory upper limit of normal. Confirmatory evidence of myocardial ischemia includes any one of the following:
Chest pain or equivalent symptoms consistent with myocardial ischemia ECG evidence of ischemia including new ST segment depression or elevation 4l mm in two or more contiguous leads.
For death, efforts are made to obtain relevant records from the hospital or the patient's primary physician, including death certificates, to determine cause.
Secondary outcomes
Secondary aims are to describe the differential efficacy of CAS and CEA by symptomatic status and by sex, contrast peri-procedural (30-day) and post-procedural morbidity and mortality, contrast the restenosis rates of CAS and CEA, evaluate differences in health-related quality of life (QOL) and cost, and identify subgroups of participants at differential risk for procedural morbidity and mortality.
Health-related QOL and functional status are assessed using the Medical Outcomes Study 36-item health status questionnaire (SF-36) and Frenchay Activities Index at baseline, one month, and one year and the Health Utilities Index (HUI) at one year. The SF-36 and several disease-specific scales are administered two weeks after the initial revascularization procedure by a trained telephone interviewer from the QOL center.
Medical resource utilization and cost data are collected for subsequent hospitalizations, medical procedures, long-term care, and outpatient care through one year. Hospital summary bills (UB-92 forms) and detailed billing statements are obtained for each patient's index hospitalization. These data are converted into measures of medical-care cost. At completion of the study, cost and QOL data will be integrated to perform a formal cost-effectiveness analysis.
Data safety and monitoring board (DSMB)
The NINDS-appointed DSMB is responsible for assuring that study participants are not exposed to unnecessary or unreasonable risks and that the study is being conducted according to high scientific and ethical standards. The DSMB is responsible for advising early termination of the trial in the event of unexpected safety concerns or if treatment differences were apparent at the pre-specified interim analyses using O'Brien-Fleming boundaries (12) . 
Sample size
The sample size of 2500 subjects was selected to provide 90% power to detect a hazard ratio of 41Á54 or o0Á49 in the composite endpoint event rates, which corresponds to greater than 1Á2% per year absolute differences, a difference similar to that shown in ACAS (7) .
Statistical analyses
Analyses are based on an intention-to-treat survival analysis and standard time-to-event statistical modeling with adjustment for major baseline covariates. A traditional difference assessment will be performed as described in the original NIH protocol, and a non-inferiority analysis for submission to the FDA. The primary goal for the NIH analysis is to identify differences between CAS and CEA in preventing endpoint events over a multi-year follow-up. Survival analyses will allow for varying lengths of follow-up. Kaplan-Meier estimates of the proportion of patients remaining free of the composite endpoint at 30-days, six-months, one-year and annually thereafter, and the associated confidence intervals will be constructed. The hazard ratio between groups will be estimated after adjustment for important covariates.
A number of secondary analyses will be conducted:
The potential for a differential treatment efficacy between symptomatic and asymptomatic participants, and between men and women, will be assessed by the inclusion of interaction terms in the proportional hazards models. A hazard ratio difference of 2Á22 or greater can be detected with 90% power.
Differences in the morphology of the treated carotid artery segment reflecting potential restenosis of the target lesion will be assessed in both groups at six months and one year by analysis of the covariance with adjustment for velocities assessed at one month post index procedure.
Differences in peri-procedural event rates will be assessed using logistic regression (logistic regression employed because of the low censoring rate in the short peri-procedural period). The anticipated event rate (stroke, death, MI) in the CEA arm of the study is 5Á7%; there will be 90% power to detect differences between treatments if the CAS complication rate is o3Á2% or 49Á3%.
Differences in post-30 day event rates will be assessed among those participants who are event-free during the first 30 days post-procedure. Unlike the peri-procedural period, the outcome for the post-procedural period is time-to-event survival analysis. Differences between groups will be assessed using the proportional hazards model; there will be 80% power to detect differences if the hazard ratio is o0Á50 or 42Á00.
Differences in other major and minor complications will be assessed using standard methods including Chi-square testing. Power to detect differences is a function of the incidence of specific complications; however, should a complication have approximately a 5% incidence, statistical power would be similar to that for peri-procedural events.
Finally, the potential for other factors that may influence the relative efficacy of CAS and CEA in subgroups will be assessed in exploratory analyses using a proportional hazards analysis. A hazard ratio 42Á20 can be detected with 90% power; however, findings will be interpreted with caution because of the exploratory nature of these analyses.
In secondary analysis of the primary endpoint, data will be imputed in order to ensure that participants who withdrew from the study early could not have biased estimated treatment effects. For each participant who withdrew from the study, the outcome for a patient matched for age and symptomatic status will be substituted. Multiple imputations will then be employed to introduce appropriate variance to the estimated treatment effects.
Two protocol-specified interim analyses were reviewed by the DSMB: after approximately 500 patients and again after approximately 1/2 of the patients were enrolled. In order to maintain maximum power for the final analysis while simultaneously protecting the overall alpha of the study, O'Brien-Fleming (12) adjustments were made to the alpha for each of these tests. The statistical costs of these adjustments have been incorporated in the power calculations. After each DSMB review, the study was recommended for continuation.
Study organization and funding
The trial was funded January 15, 1999 by the NINDS with support from Abbott Vascular, Inc. (originally Guidant). In May, 2003, the Investigational Device Exemption (IDE) sponsorship, with reporting responsibility to the FDA, was transferred from Guidant to CREST. Enrollment began in December 2000 and ended in July 2008 with 2522 participants.
Summary
CREST is a prospective, randomized, parallel, two-arm, multicenter trial, designed to compare the efficacy of CAS versus CEA in preventing stroke. The primary comparison outcome is the occurrence of any stroke, MI, or death during a 30-day peri-procedural period, and ipsilateral stroke during the follow-up period of up to four years in patients with extracranial carotid stenosis. Conventional-risk participants with symptomatic carotid stenosis (Z50% by angiography, Z70% by ultrasound, or Z70% by CTA/MRA) or asymptomatic carotid stenosis (Z60% by angiography, Z70% by ultrasound, or Z80% by CTA/MRA) are randomized to CEA or CAS in a 1 : 1 ratio. Secondary aims contrast CAS and CEA by symptomatic status, in men and women, by restenosis rates, by health-related quality of life, and by cost. With 2522 randomized patients at 117 U.S. and Canadian sites, CREST has been designed to have 90% power to detect annual treatment differences of 1Á2% in CEA and CAS primary endpoints.
